What is a Kit in a Box product?<\/a><\/span><\/p>\n\n\n\n At Nordic Bioscience, our approach to measurement is rooted in decades of innovation and a deep understanding of fibrosis. As the originators of PRO\u2011C3, we perfected the biomarker over 15+ years of clinical trials, built on more than 30 years of expertise in extracellular matrix biomarkers. Today, PRO-C3\/nordicPRO\u2011C3\u2122 is a household name known to ensure you receive data that is both precise and actionable.<\/p>\n\n\n\n As an efficacy and pharmacodynamic biomarker, nordicPRO\u2011C3\u2122 (PRO-C3) is widely used in clinical trials to monitor treatment response, demonstrate target engagement and confirm mechanism of action. In addition, its dynamic nature makes it ideal for tracking changes in fibrosis over time.<\/p>\n\n\n As a prognostic biomarker, nordicPRO-C3\u2122 supports patient selection by identifying individuals more likely to experience disease progression or clinical outcomes \u2014 helping enrich trial populations, boost statistical power, and increase the likelihood of success.<\/p>\n\n\n\n NordicPRO C3\u2122 has demonstrated value in liver diseases such as metabolic-associated fatty liver disease (MAFLD)<\/a>, alcohol-related liver fibrosis<\/a>, disease progression and clinical outcomes. Beyond liver disease, nordicPRO-C3\u2122 is widely used in research on lung fibrosis, tumor fibrosis (FDA-supported)<\/a>, and other conditions where fibrosis plays a central role.<\/p>\n\n\n\n NordicPRO-C3\u2122 provides a powerful tool for monitoring treatment efficacy and tracking disease progression over time. Furthermore, it serves as a critical decision-making tool in clinical trials, helping researchers assess treatment impact, understand the mechanism of action, and accelerate drug development.<\/p>\n\n\n\n We focus on your research needs:<\/strong><\/p>\n\n\n\n Disclaimer:<\/strong> This biomarker is for research use only. It is not intended for use in diagnostic procedures or therapeutic interventions.<\/p>\n\n\n\n Clinical trials are a critical and costly step in drug development. Reducing trial size while maintaining robust data is essential for accelerating market entry and managing costs.<\/p>\n\n\n\n NordicPRO\u2011C3\u2122 transforms clinical trial efficiency by enabling precise pre-stratification of patients. By identifying individuals with active fibrosis who are most likely to respond to treatment, nordicPRO\u2011C3\u2122 helps optimize patient selection, ensuring trials enroll the right participants from the start. This not only enhances trial success rates but also significantly reduces the number of enrollees needed\u2014saving time, resources, and costs while increasing confidence in the therapeutic\u2019s efficacy.<\/p>\n\n\n\n By integrating nordicPRO\u2011C3\u2122 into clinical trial design, drug developers can streamline recruitment, improve study outcomes, and bring innovative fibrosis-targeted therapies to market faster.<\/p>\n\n\n\n Understanding a drug\u2019s precise mode of action (MOA) is critical for evaluating safety, optimizing efficacy, and advancing precision medicine. However, in many cases, the exact MOA remains unclear.<\/p>\n\n\n\n NordicPRO\u2011C3\u2122 provides valuable insights into MOA by detecting active fibrosis formation. A key process in disease progression and treatment response. By integrating nordicPRO\u2011C3\u2122 into clinical trials, researchers gain a deeper understanding of how a drug interacts with fibrotic pathways, supporting data-driven decisions on safety, efficacy, and patient stratification.<\/p>\n\n\n\n Not all patients respond equally to treatment\u2014many experience varying levels of efficacy and safety, while some fail to respond at all. This leads to wasted resources, ineffective care, and increased healthcare costs.<\/p>\n\n\n\n NordicPRO\u2011C3\u2122 changes this by providing a powerful tool to monitor treatment response in fibrotic diseases. By measuring active fibrosis, nordicPRO\u2011C3\u2122 helps identify patients who are most likely to benefit from specific therapies. This enables clinicians to make informed treatment decisions, reduces unnecessary treatments, and supports reimbursement strategies.<\/p>\n\n\n\n Effective drug development requires real-time insights into treatment efficacy and pharmacodynamic effects to ensure therapies are working as intended. Traditional endpoints often fail to capture early dynamic changes in fibrosis, delaying crucial adjustments in clinical strategies.<\/p>\n\n\n\n nordicPRO\u2011C3\u2122 offers a dynamic solution by enabling longitudinal monitoring of active fibrosis remodeling, providing direct evidence of a drug\u2019s impact on fibrotic pathways already in phase IB. By tracking changes in nordicPRO\u2011C3\u2122 levels over time, researchers can assess whether a therapy is effectively reducing fibrosis, determine optimal dosing strategies, and detect early signs of treatment response.<\/p>\n\n\n\n By integrating nordicPRO\u2011C3\u2122 into clinical trials and treatment protocols, drug developers and clinicians gain a powerful pharmacodynamic biomarker that validates drug efficacy, supports regulatory decision-making, and accelerates the path to precision fibrosis therapies.<\/p>\n\n\n\n Liver Diseases<\/p>\n\n\n\n Lung Diseases<\/p>\n\n\n\n Kidney Diseases<\/p>\n\n\n\n Cardiovascular Diseases<\/p>\n\n\n\n Systemic Fibrotic and Autoimmune Diseases<\/p>\n\n\n\n Solid cancers<\/p>\n\n\n\n A biomarker of collagen type I degradation is associated with cardiovascular events and mortality in patients with atherosclerosis.<\/a><\/p>\n\n\n\n A biomarker perspective on the acute effect of exercise with and without impact on joint tissue turnover: an exploratory randomized cross-over study<\/a><\/p>\n\n\n\n A dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model<\/a><\/p>\n\n\n\n Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis<\/a><\/p>\n\n\n\n ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis<\/a><\/p>\n\n\n\n Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART<\/a><\/p>\n\n\n\n Collagen Type III and VI Turnover in Response to Long-Term Immobilization<\/a><\/p>\n\n\n\n Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients<\/a><\/p>\n\n\n\n Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis<\/a><\/p>\n\n\n\n Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to anti-fibrotic therapy<\/a><\/p>\n\n\n\n Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients<\/a><\/p>\n\n\n\n Misbalance in type III collagen formation\/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease<\/a><\/p>\n\n\n\n Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease<\/a><\/p>\n\n\n\n Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C<\/a><\/p>\n\n\n\n PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease<\/a><\/p>\n\n\n\n PRO-C3-levels in patients with HIV\/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension<\/a><\/p>\n\n\n\nKey features and values<\/summary>\n
\n
Description<\/summary>\n
![\"\"](\"https:\/\/www.nordicbioscience.com\/wp-content\/uploads\/2025\/04\/visit-webp-1024x794.webp\")
\n
Patient selection for more efficient clinical trails <\/h2>\n\n\n\n
Actionable insights into drug mode of action<\/h2>\n\n\n\n
Monitor drug response<\/h2>\n\n\n\n
Monitoring treatment efficacy and pharmacodynamics<\/h2>\n\n\n\n
Which diseases can nordicPRO\u2011C3\u2122 be used in?<\/summary>\n
\n
\n
\n
\n
\n
\n
Publications<\/summary>\n